Wednesday, July 8, 2026

Patent intelligence · US

US 9517275

Targeted therapy for the prevention of restenosis in the cardiovascular system

granted A61KA61K33/00A61K38/00A61K47/66
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 10
Applicant portfolio 595
Patent details — US 9517275
Jurisdiction
US
Status
granted
Grant date
Dec 13, 2016
Expiration
Dec 8, 2036
Claims
21
CPC classes
A61K, A61K33/00, A61K38/00, A61K47/66
View on Google Patents ↗

Quick answer

US 9517275 (Targeted therapy for the prevention of restenosis in the cardiovascular system) is held by Northwestern University. Status: granted. Granted Dec 13, 2016. Expires Dec 8, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
21
CPC classes
A61K, A61K33/00, A61K38/00, A61K47/66

More from Northwestern University

Related pharmaceutical patents in our USPTO index.

  1. US 12421280

    Insulin like growth factor binding protein bioactive peptide fragments

    Northwestern University · Expires Sep 18, 2045

    granted
  2. US 12414995

    Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

    Northwestern University · Expires Sep 11, 2045

    granted
  3. US 12414981

    JNK inhibitors for use in treating and preventing neurodegenerative disorders

    Northwestern University · Expires Sep 11, 2045

    granted
  4. US 12414963

    Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin

    Northwestern University · Expires Sep 11, 2045

    granted
  5. US 12415995

    Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

    Northwestern University · Expires Sep 11, 2045

    granted
  6. US 12409205

    Nanomolecules for the treatment of inflammatory bowel diseases

    Northwestern University · Expires Sep 4, 2045

    granted
  7. US 12410474

    Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient

    Northwestern University · Expires Sep 4, 2045

    granted
  8. US 12404533

    Bioconjugate vaccines' synthesis in prokaryotic cell lysates

    Northwestern University · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 9517275?

US 9517275 (Targeted therapy for the prevention of restenosis in the cardiovascular system) is held by Northwestern University. Status: granted. Granted Dec 13, 2016. Expires Dec 8, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9517275?

Northwestern University is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 595 pharmaceutical patents for this assignee.

When does US 9517275 expire?

Our index shows an expiration date of Dec 8, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.